Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.60 |
| ▸ | ABL2 | P42684 | 6/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | CDK8 | P49336 | 1/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 3/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614760 | 0.90 | ABL1 (0.60) | ABL1ABL2CDK1CDK2CDK8 | |
| SCHEMBL19307227 | 0.90 | ABL1 (0.60) | ABL1ABL2CDK1CDK2CDK8 | |
| SCHEMBL20214713 | 0.89 | ABL1 (0.59) | ABL1ABL2CDK1CDK2CDK8 | |
| SCHEMBL20214729 | 0.89 | ABL1 (0.59) | ABL1ABL2CDK1CDK2CDK8 | |
| SCHEMBL24448260 | 0.86 | ABL1 (0.73) | ABL1ABL2CDK1CDK2CDK8 | |
| SCHEMBL29614931 | 0.86 | ABL1 (0.65) | ABL1ABL2CDK1CDK2CDK8 | |
| SCHEMBL19307164 | 0.86 | ABL1 (0.65) | ABL1ABL2CDK1CDK2CDK8 | |
| SCHEMBL29614794 | 0.86 | ABL1 (0.62) | ABL1ABL2FGFR4MAPK14SRC | |
| SCHEMBL19307181 | 0.86 | ABL1 (0.62) | ABL1ABL2FGFR4MAPK14SRC | |
| SCHEMBL19316705 | 0.85 | ABL1 (0.71) | ABL1ABL2CDK1CDK2CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2021-08-05 | — | — | US | disclosed |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | ABL1 3753/4885ABL2 4577/4885CDK1 2504/4885 |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | ABL1 3753/4885ABL2 4577/4885CDK1 2504/4885 |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | ABL1 4516/4885ABL2 2755/4885CDK1 3629/4885 |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | XBP1, ERN1, ERN2 | ABL1 3590/4885ABL2 4545/4885CDK1 2364/4885 |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | ABL1 3753/4885ABL2 4577/4885CDK1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.